Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
Earnings Data
Report Date
Aug 11, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.43Last Year’s EPS
-0.3Same Quarter Last Year
Moderate Buy
Based on 21 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: -9.52%
|Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with notable achievements such as FDA Priority Review for EMPAVELI and maintaining market leadership with SYFOVRE. However, revenue challenges due to inventory dynamics and funding shortages for co-pay assistance programs were significant concerns.Company Guidance
During the Q1 2025 earnings call for Apellis Pharmaceuticals, the company provided several key metrics and guidance. SYFOVRE injection demand grew by 4% quarter-over-quarter, with approximately 92,000 doses delivered, including 82,000 commercial doses and 10,000 samples. Despite this growth, SYFOVRE revenue fell short of expectations, coming in at $130 million, primarily due to inventory drawdown and a co-pay assistance funding shortage, which impacted revenue by approximately $10 million. SYFOVRE maintains over 60% market share, with new patient starts surpassing 50%, reaching 55% by late April. For EMPAVELI, the FDA granted Priority Review for C3G and IC-MPGN, with a PDUFA date set for July 28, 2025. The Phase 3 VALIANT study showed significant results, including a 68% reduction in proteinuria. Apellis expects operating expenses in 2025 to remain in line with 2024 levels, with $358 million in cash and cash equivalents at the end of Q1, providing confidence in funding the business to profitability.EMPAVELI Priority Review and Phase 3 Success
EMPAVELI received Priority Review designation from the FDA for C3G and IC-MPGN with a PDUFA date of July 28. The Phase 3 VALIANT results showed a 68% reduction in proteinuria, stabilization of kidney function, and substantial clearing of C3c staining.
SYFOVRE Market Leadership
SYFOVRE maintains over 60% market share in geographic atrophy with new patient starts exceeding 50% in Q1 2025 and reaching 55% by late April.
Financial Stability
Apellis has $358 million in cash and cash equivalents, expecting this to be sufficient to fund the business to profitability.
EMPAVELI Blockbuster Potential
U.S. launch of EMPAVELI in C3G and IC-MPGN expected to represent Apellis' third new product launch in four years, expanding presence in rare nephrology indications.
---
APLS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
APLS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 07, 2025 | $19.12 | $17.99 | -5.91% |
| Feb 28, 2025 | $26.00 | $25.15 | -3.27% |
| Nov 05, 2024 | $28.56 | $28.08 | -1.68% |
| Aug 01, 2024 | $39.60 | $36.00 | -9.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Apellis Pharmaceuticals Inc (APLS) report earnings?
Apellis Pharmaceuticals Inc (APLS) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
What is Apellis Pharmaceuticals Inc (APLS) earnings time?
Apellis Pharmaceuticals Inc (APLS) earnings time is at Aug 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is APLS EPS forecast?
APLS EPS forecast for the fiscal quarter 2025 (Q2) is -0.43.
---